Fennec Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Mar '26 Mar 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Market Cap	199	216	174
Market Cap Growth	11.38%	24.45%	-
Enterprise Value	162.31	179.71	166.67
Last Close Price	5.77	7.70	6.32
PE Ratio	-	-22.65	-316.00
Forward PE	30.69	15.88	-
PS Ratio	4.46	4.85	3.66
PB Ratio	5.56	6.10	-29.63
P/TBV Ratio	4.65	6.20	-29.38
P/FCF Ratio	-	-17.36	6.45
P/OCF Ratio	-	-17.36	6.45
EV/Sales Ratio	3.64	4.03	3.51
EV/EBITDA Ratio	-	-28.61	64.90
EV/EBIT Ratio	-	-28.61	64.90
EV/FCF Ratio	-	-14.41	6.18
Debt / Equity Ratio	-	0	-3.29
Debt / EBITDA Ratio	-	-	7.53
Debt / FCF Ratio	-	-	0.72
Net Debt / Equity Ratio	-1.04	-1.04	1.24
Net Debt / EBITDA Ratio	5.86	5.86	-2.84
Net Debt / FCF Ratio	2.95	2.95	-0.27
Asset Turnover	0.77	0.77	1.06
Inventory Turnover	2.87	2.87	3.00
Quick Ratio	5.71	5.71	5.71
Current Ratio	6.37	6.37	6.38
Return on Equity (ROE)	-65.82%	-65.82%	7.43%
Return on Assets (ROA)	-11.00%	-11.00%	35.09%
Return on Invested Capital (ROIC)	-36.15%	-36.15%	135.44%
Return on Capital Employed (ROCE)	-12.81%	-12.81%	6.75%
Earnings Yield	-4.89%	-4.42%	-0.32%
FCF Yield	-	-5.76%	15.51%
Buyback Yield / Dilution	-4.70%	-4.70%	-
Total Shareholder Return	-4.70%	-4.70%	-

Updated Mar 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q